한글목차

갑상선암 진단 동향 및 전망

세계 갑상선암 진단 시장의 미래는 병원, 관련 연구소, 독립 진단 연구소, 영상 진단 센터, 암 연구소 시장의 기회로 인해 유망합니다. 세계 갑상선암 진단 시장은 2024년부터 2030년까지 5.5%의 CAGR로 2030년까지 약 76억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 갑상선암 발병률 증가, 실시간 진단 및 치료에 대한 관심 증가, 갑상선암에 대한 인식 증가 등입니다.

• Lucintel의 예측에 따르면, 검사 유형별로는 고해상도 및 실시간 이미지 검사에 대한 수요 증가로 인해 이미지 검사가 가장 큰 부문을 차지할 것으로 예상됩니다.
• 최종사용자 부문에서는 병원의 암 진단 환자 증가, 소비자 인식 증가, 세계 헬스케어 인프라에 대한 투자 증가로 인해 병원이 예측 기간 동안 가장 큰 부문으로 남을 것으로 보입니다.
• 지역별로는 북미가 갑상선암의 유병률 증가, 의료비 증가, 미국 정부의 적극적인 인식 개선, 진단 및 치료 노력으로 인해 가장 큰 지역으로 남을 것으로 보입니다.

갑상선암 진단 시장의 전략적 성장 기회

갑상선암 진단 시장은 다양한 응용 분야에서 빠르게 성장하고 있습니다. 이러한 기회는 기술 개발, 의료비 지출 증가, 환자 치료의 개선으로 인해 발생합니다.

• 새로운 AI 지원 진단 도구 개발 : 최신 진단 도구의 AI 강화 기능은 성장 전망을 창출하고, AI 알고리즘은 수많은 이미지를 읽고 미세한 특징을 감지하여 더 정확한 결론을 내릴 수 있으며, AI 솔루션의 출현은 근육 장애 진단의 품질과 속도를 향상시켜 시장 성장에 기여할 것입니다. 시장 성장에 기여할 것입니다.
• 비침습적인 새로운 진단 방법 : 혈액 생검 및 영상 진단과 같은 첨단 기술이 의료 분야에서 널리 보급되고 있습니다. 이러한 비침습적 방법은 진단을 보다 편리하게 하고 환자의 고통을 줄일 수 있습니다. 이러한 추세는 시장 성장의 큰 기회가 될 것입니다.
• 분자진단 응용의 증가 : 유전학 검사 및 유전체 검사와 같은 분자진단의 채택이 증가하는 추세가 나타나고 있으며, 이는 더 많은 수익을 창출할 것입니다. 이러한 기술은 갑상선암의 생물학적 측면을 밝혀내고, 치료 접근법을 안내하고, 진단 정확도를 높일 수 있습니다.
• 기존 조기발견 프로그램 강화 : 갑상선암 조기발견 프로그램 구축이 주목받고 있습니다. 이러한 프로그램은 질병의 조기 발견을 용이하게함으로써 치료 비용을 낮출 수 있기 때문에 유익합니다. 조기 발견 프로그램에는 성장 잠재력이 있습니다.
• 신시장 개척 : 아시아 및 라틴아메리카의 신흥 시장은 헬스케어에 대한 수용도가 높아지고 갑상선암에 대한 인식이 높아짐에 따라 성장 기회를 제공할 것으로 보입니다. 진단 능력의 확대는 조기 진단과 치료 접근성을 높여 시장 성장으로 이어질 것으로 예상됩니다.

이러한 전략적 성장 기회를 활용하면 차세대 갑상선암 진단 시장을 창출하고, 진단의 질을 개선하고, 환자 접근성을 높이고, 시장 성장을 촉진할 수 있습니다. 이러한 기회를 활용하면 갑상선암의 진단과 치료가 더욱 향상될 것입니다.

갑상선암 진단 시장의 촉진요인 및 과제

갑상선암 진단 시장은 성장과 개척에 영향을 미치는 몇 가지 촉진요인과 과제에 영향을 받고 있습니다. 이러한 요인에는 시장 구조를 형성하는 기술 변화, 시장 경제, 규제 정책 등이 포함됩니다.

갑상선암 진단 시장을 주도하는 요인은 다음과 같습니다.

• 기술 발전 : 영상 진단, AI 및 분자진단의 새로운 장치가 시장을 발전시킬 것입니다. 이러한 기술은 진단과 개입이 보다 효과적이고 신속하게 이루어지도록 보장하여 환자 결과를 개선하고 시장 성장에 기여합니다.
• 의료 투자 증가 : 의료 인프라 및 연구에 대한 자금이 증가하여 진단 장비의 개선이 촉진되고 있습니다. 투자 증가는 갑상선암 진단 산업에서 새로운 기술 개발을 도입하여 생산성을 높일 수 있습니다.
• 검진 프로그램에 대한 인식과 보급률 증가 : 갑상선암에 대한 민감도가 높아져 정확한 일반 검진 프로그램이 시행되고 있습니다. 이러한 인식은 시장 성장에 긍정적인 영향을 미칩니다.
• 갑상선암 환자 증가 : 전 세계 갑상선암 환자 증가로 인해 진단 서비스에 대한 수요가 증가하고 있습니다. 치료를 받기 위해 새로운 진단 방법을 찾는 환자가 증가하고 있습니다.
• 표적 치료의 채택 증가 : 개인화된 의료, 특히 표적 치료와 개인화된 진단법으로의 전환이 성장을 촉진하고 있습니다. 이러한 발전은 환자의 복지를 향상시키고 시장 역학을 변화시키는 새로운 방법을 설계하는 데 도움이 됩니다.

갑상선암 진단 시장의 과제는 다음과 같습니다.

• 고가의 고급 진단 검사 : 고급 진단 검사는 비용이 많이 듭니다. 고급 영상 진단 장비의 비용은 더 간단한 절차에 비해 높기 때문에 가난한 지역에서 접근과 사용을 방해하고 있습니다. 이 비용 문제는 진단 서비스의 발전과 공평한 제공을 방해합니다.
• 규제적 제약 : 복잡한 규제로 인해 새로운 진단기기를 승인받는 데 비용과 시간이 많이 소요됩니다. 이러한 장애물은 컴플라이언스 타임라인과 경제적 측면에 영향을 미칠 수 있습니다.
• 농촌 지역의 제한된 의료 서비스 이용 가능성 : 농촌 및 의료 서비스가 부족한 지역에서는 진단 서비스에 대한 접근성이 여전히 제한되어 있습니다. 이러한 지역에서 진단 도구를 쉽게 이용할 수 있고 저렴하게 만드는 것은 시장 성장과 의료 서비스 제공 시스템을 강화하는 데 매우 중요합니다.

갑상선암 진단 시장의 성장은 기술 발전, 자금 조달 증가, 질병에 대한 인식 증가 등의 요인에 의해 형성됩니다. 그러나 높은 비용, 규제 문제, 접근성 제한 등의 문제는 여전히 해결되지 않아 효과적인 진단 및 치료에 대한 시장의 잠재력을 제한하고 있습니다.

목차

제1장 주요 요약

제2장 세계의 갑상선암 진단 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 갑상선암 진단 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 갑상선암 진단 시장, 제품 유형별
  • 기기
  • 소모품과 액세서리
• 세계의 갑상선암 진단 시장, 검사 유형별
  • 영상 검사
  • 생검
  • 혈액 검사
  • 기타
• 세계의 갑상선암 진단 시장, 최종 용도별
  • 병원
  • 관련 실험실
  • 독립 진단 연구소
  • 영상 진단 센터
  • 암 조사 기관
  • 기타

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 세계의 갑상선암 진단 시장
• 북미의 갑상선암 진단 시장
• 유럽의 갑상선암 진단 시장
• 아시아태평양의 갑상선암 진단 시장
• 기타 지역의 갑상선암 진단 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 제품 유형별 세계의 갑상선암 진단 시장 성장 기회
  • 검사 유형별 세계의 갑상선암 진단 시장 성장 기회
  • 세계의 갑상선암 진단 시장의 최종 용도별 성장 기회
  • 지역별 세계의 갑상선암 진단 시장 성장 기회
• 세계의 갑상선암 진단 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 갑상선암 진단 시장 능력 확대
  • 세계의 갑상선암 진단 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Abbott
• Hoffmann-La Roche
• Thermo Fisher Scientific
• Siemens Healthcare
• Bio-Rad Laboratories
• General Electric
• Koninklijke Philips
• Toshiba Corporation
• Agilent Technologies
• Illumina

영문목차

Thyroid Cancer Diagnostic Trends and Forecast

The future of the global thyroid cancer diagnostic market looks promising with opportunities in the hospital, associated lab, independent diagnostic laboratory, diagnostic imaging center, and cancer research institute markets. The global thyroid cancer diagnostic market is expected to reach an estimated $7.6 billion by 2030 with a CAGR of 5.5% from 2024 to 2030. The major drivers for this market are the increasing incidence of thyroid cancer, the growing focus on real-time diagnosis and treatment, and rising awareness of thyroid cancer.

• Lucintel forecasts that, within the test type category, imaging testing will remain the largest segment due to the increasing demand for high-resolution and real-time image testing.
• Within the end-use category, hospitals will remain the largest segment over the forecast period due to the growing inflow of cancer diagnosis patients in hospitals, increasing consumer awareness, and growing investments in healthcare infrastructure across the globe.
• In terms of regions, North America will remain the largest region due to the increasing prevalence of thyroid cancer, rising healthcare expenditure, and favorable government initiatives in the US for awareness, diagnosis, and treatment.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Thyroid Cancer Diagnostic Market

The thyroid cancer diagnostic industry is quickly adapting to emerging trends. These trends result from technological advancements, enriched research, and transformations in social behavior, which foster new avenues for improved service and patient care.

• Enabling Sound Commitments in Diagnostics Using AI: The application spectrum of AI, machine learning, and imaging technologies in the detection and risk prediction of cancer is constantly widening. For instance, the patterns that enhance the prediction of thyroid cancer detection using AI algorithms are often overlooked by human readers. This trend helps achieve better and earlier SARs, thereby lowering health risks for patients.
• Enhancement of Liquid Biopsy Potentials: Liquid biopsy is emerging as a viable, non-invasive method to identify cancer-causing markers in the blood. This technology can detect the presence and progression of thyroid cancer without requiring a tissue biopsy. It significantly improves the quality of personalized medicine.
• Formation of Molecular Diagnostics with Genetic Testing: Molecular diagnostics and genetic testing provide further insights into thyroid cancer at the molecular level. This includes advanced techniques such as next-generation sequencing (NGS), which enable the detection of mutations and other biomarkers linked to thyroid cancer for personalized therapy and diagnostics.
• Using Advanced Imaging Techniques: The development of imaging technologies, including high-frequency ultrasound and sophisticated MRI, bolsters the ability to identify and classify thyroid nodules and cancer. These technologies offer higher resolution and precision, leading to earlier and more accurate diagnoses, which are essential for patient treatment.
• Patient-Focused Diagnostics: There is an increasing emphasis on incorporating patient-centered diagnostic methods designed to cater to population needs and specific clinical instances. This trend aims to compile information on patients' desires and medical history to create unique diagnostic and therapeutic approaches focused on the individual, enhancing patient experience and outcomes.

These trends are transforming the thyroid cancer diagnostic market by increasing accuracy, facilitating early diagnosis, and integrating patient care services. They represent significant steps forward that will enhance the feasibility of developing new diagnostic modalities with safer and more effective therapeutics, benefiting patient well-being and reducing healthcare costs.

Recent Developments in the Thyroid Cancer Diagnostic Market

Recent achievements in the thyroid cancer diagnostic market reflect significant sophistication and growth in technology and methodology. This evolution is supported by studies, technological innovations, and investments in healthcare that improve direct patient care and assist in managing thyroid disease.

• Precision Medicine Approaches: In recent years, precision medicine has evolved into a paradigm for determining the most appropriate diagnostics for thyroid cancer imaging based on the patient's unique genetic and molecular characteristics. This approach allows for greater precision in accurate diagnoses and effective therapeutic interventions, enhancing patient care and minimizing treatment resource waste.
• Advanced Imaging Technologies: The implementation of new technologies, including high-frequency rescue ultrasound and molecular imaging studies, contributes to better thyroid nodule detection and characterization. These technologies provide high-quality images and information, thus enhancing sensitivity and increasing positive predictive value.
• AI and Machine Learning Integration: Improved imaging techniques enable the use of artificial intelligence and machine learning in imaging processes, enhancing image analysis and detecting both subtle and conspicuous features suggesting thyroid cancer. These technologies increase the likelihood of relevant findings and improve the reliability of positive diagnoses.
• Liquid Biopsy Innovations: Liquid biopsy techniques are being refined to provide more accurate detection of thyroid cancer-associated markers in blood samples. This less invasive procedure is preferable and more effective than conventional tissue biopsies for earlier diagnosis and disease follow-up.
• Advances in Molecular Diagnostics: Technological innovations for molecular diagnostics, especially revolutionary next-generation sequencing, have enabled more detailed analyses of the genetic and molecular features of thyroid cancers. These developments provide clearer diagnoses and efficient treatment procedures, improving the services received by patients.

These advancements are reshaping the thyroid cancer diagnostic market by increasing diagnostic accuracy, enabling early cancer detection, and providing tailored therapies to affected individuals. Such advancements are crucial for enhancing condition management and patient welfare.

Strategic Growth Opportunities for Thyroid Cancer Diagnostic Market

The thyroid cancer diagnostic market is experiencing rapid growth across various applications. These opportunities stem from technological developments, increased healthcare expenditure, and improvements in patient care.

• Development of New AI-Enabled Diagnostic Tools: The AI-enhanced capabilities of modern diagnostic tools create growth prospects. AI algorithms can read numerous images, detecting minute features and making conclusions more precise. The emergence of AI solutions enhances the quality and speed of diagnosing muscle disorders, contributing to market growth.
• New Non-Invasive Ways to Diagnose: Advanced techniques, including blood biopsies and imaging, are gaining traction in the medical field. These non-invasive methods make diagnosis more convenient and less distressing for patients. This trend represents a significant growth opportunity in the market.
• Increase in the Application of Molecular Diagnostics: There is an emerging trend toward increased adoption of molecular diagnostics, such as genetic and genomic testing, which will generate more revenue. These technologies elucidate the biological aspects of thyroid cancer, guiding treatment approaches and enhancing diagnostic accuracy.
• Enhancement of Existing Early Detection Programs: Attention is being directed toward instituting early detection programs for thyroid cancer. Such programs are advantageous, as they can lower therapeutic expenses by facilitating earlier disease detection. There is potential for growth in early detection initiatives.
• Opening Up to New Markets: Emerging markets in Asia and Latin America are likely to provide growth opportunities due to increasing healthcare acceptance and rising awareness of thyroid cancer. Expanding diagnostic capabilities is expected to lead to market growth by increasing access to early diagnosis and treatment.

Leveraging these strategic growth opportunities will help create the next generation of the thyroid cancer diagnostic market, enhancing diagnostic quality, increasing patient accessibility, and promoting market growth. Utilizing these opportunities will further improve the diagnosis and treatment of thyroid cancer.

Thyroid Cancer Diagnostic Market Driver and Challenges

The market for thyroid cancer diagnosis is influenced by several drivers and challenges that affect its growth and development. These factors include technological changes, market economics, and regulatory policies that shape the market structure.

Factors driving the thyroid cancer diagnostic market include:

• Technological Advancements: New devices in imaging, AI, and molecular diagnostics propel the market forward. These technologies ensure that diagnoses and interventions are conducted more effectively and quickly, improving patient outcomes and contributing to market growth.
• Increasing Healthcare Investments: More funding for healthcare infrastructure and research is facilitating the improvement of diagnostic equipment. Increased investment enhances productivity by embracing new technological developments in the thyroid cancer diagnostic industry.
• Growing Awareness and Prevalence of Screening Programs: There is improved sensitivity to thyroid cancer and the implementation of accurate general screening programs. This awareness positively affects market growth.
• Increase in Thyroid Cancer Cases: The rising number of thyroid cancer patients worldwide increases the demand for diagnostic services. More patients seek new diagnostic procedures to receive treatment.
• Increasing Adoption of Targeted Therapies: The shift toward personalized medicine, especially targeted therapies and tailored diagnostic methods, is driving growth. Such advancements help design new methods that enhance patient welfare and change market dynamics.

Challenges in the thyroid cancer diagnostic market include:

• Expensive Advanced Diagnostic Tests: High costs associated with sophisticated imaging instruments, compared to simpler procedures, hinder availability and use in poorer regions. This cost issue hampers the development and equitable provision of diagnostic services.
• Regulatory Constraints: Obtaining regulatory approvals for new diagnostic devices is costly and time-consuming due to complex regulations. These impediments can affect compliance timelines and economic aspects.
• Limited Availability of Health Services in Rural Areas: Access to diagnostic services in rural and underserved areas remains limited. Making diagnostic tools accessible and affordable in these regions is crucial for market growth and enhancing healthcare delivery systems.

Factors such as technological progress, increased funding, and heightened awareness about diseases shape the growth of the thyroid cancer diagnostic market. However, challenges such as high costs, regulatory issues, and limited accessibility remain unaddressed, limiting the market's potential for effective diagnosis and treatment.

List of Thyroid Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies thyroid cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the thyroid cancer diagnostic companies profiled in this report include-

• Abbott
• Hoffmann-La Roche
• Thermo Fisher Scientific
• Siemens Healthcare
• Bio-Rad Laboratories
• General Electric
• Koninklijke Philips
• Toshiba Corporation
• Agilent Technologies
• Illumina

Thyroid Cancer Diagnostic by Segment

The study includes a forecast for the global thyroid cancer diagnostic by product type, test type, end use, and region.

Thyroid Cancer Diagnostic Market by Product Type [Analysis by Value from 2018 to 2030]:

• Instruments
• Consumables & Accessories

Thyroid Cancer Diagnostic Market by Test Type [Analysis by Value from 2018 to 2030]:

• Imaging Test
• Biopsy
• Blood Test
• Others

Thyroid Cancer Diagnostic Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospital
• Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

Thyroid Cancer Diagnostic Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Thyroid Cancer Diagnostic Market

The thyroid cancer diagnostic market is dynamically evolving due to technological development, growing awareness, and increased funding for research. The United States, China, Germany, India, and Japan are at the forefront of this evolution, providing novel diagnostic approaches and better healthcare systems. These developments are transforming thyroid cancer detection, improving effectiveness, and enabling earlier detection.

• United States Progress: The U.S. is advancing in precision medicine and liquid biopsy. Research-oriented tests for genetic and molecular screening are being developed, resulting in more efficient early diagnostic markers and treatment modalities. This bidirectional technology transfer is further enhanced by the FDA's fast-tracking of new diagnostic devices.
• China: By expanding investment in research and development, China aims to broaden its diagnostic capabilities. Recent developments include the use of AI in imaging and diagnostics to assist in early thyroid cancer detection, with a focus on enhancing services for underserved rural populations.
• Germany: Germany is at the forefront of applying emerging imaging techniques, such as super-resolution ultrasound and molecular imaging for patients. The country is also making strides in searching for additional biomarkers and non-invasive techniques, aimed at improving diagnostic quality and outcomes.
• India: In India, initiatives are underway to enhance access to affordable diagnostic services and products. Innovations include low-cost molecular assays and new imaging technologies, alongside efforts to train healthcare providers for more accurate diagnoses and better services in underserved areas.
• Japan: Japan is advancing the development of new diagnostic modalities, particularly next-generation molecular diagnostics and imaging. The country is also enhancing existing early detection programs, expanding public health campaigns, and applying AI-based diagnostic processes to improve accuracy and efficiency in thyroid cancer diagnosis.

Features of the Global Thyroid Cancer Diagnostic Market

Market Size Estimates: Thyroid cancer diagnostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Thyroid cancer diagnostic market size by product type, test type, end use, and region in terms of value ($B).

Regional Analysis: Thyroid cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, test types, end uses, and regions for the thyroid cancer diagnostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the thyroid cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the thyroid cancer diagnostic market by product type (instruments and consumables & accessories), test type (imaging test, biopsy, blood test, and others), end use (hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Thyroid Cancer Diagnostic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Thyroid Cancer Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Thyroid Cancer Diagnostic Market by Product Type
  • 3.3.1: Instruments
  • 3.3.2: Consumables & Accessories
• 3.4: Global Thyroid Cancer Diagnostic Market by Test Type
  • 3.4.1: Imaging Test
  • 3.4.2: Biopsy
  • 3.4.3: Blood Test
  • 3.4.4: Others
• 3.5: Global Thyroid Cancer Diagnostic Market by End Use
  • 3.5.1: Hospital
  • 3.5.2: Associated Labs
  • 3.5.3: Independent Diagnostic Laboratories
  • 3.5.4: Diagnostic Imaging Centers
  • 3.5.5: Cancer Research Institutes
  • 3.5.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Thyroid Cancer Diagnostic Market by Region
• 4.2: North American Thyroid Cancer Diagnostic Market
  • 4.2.1: North American Market by Test Type: Imaging Test, Biopsy, Blood Test, and Others
  • 4.2.2: North American Market by End Use: Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others
• 4.3: European Thyroid Cancer Diagnostic Market
  • 4.3.1: European Market by Test Type: Imaging Test, Biopsy, Blood Test, and Others
  • 4.3.2: European Market by End Use: Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others
• 4.4: APAC Thyroid Cancer Diagnostic Market
  • 4.4.1: APAC Market by Test Type: Imaging Test, Biopsy, Blood Test, and Others
  • 4.4.2: APAC Market by End Use: Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others
• 4.5: ROW Thyroid Cancer Diagnostic Market
  • 4.5.1: ROW Market by Test Type: Imaging Test, Biopsy, Blood Test, and Others
  • 4.5.2: ROW Market by End Use: Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Thyroid Cancer Diagnostic Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Thyroid Cancer Diagnostic Market by Test Type
  • 6.1.3: Growth Opportunities for the Global Thyroid Cancer Diagnostic Market by End Use
  • 6.1.4: Growth Opportunities for the Global Thyroid Cancer Diagnostic Market by Region
• 6.2: Emerging Trends in the Global Thyroid Cancer Diagnostic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Thyroid Cancer Diagnostic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Thyroid Cancer Diagnostic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Hoffmann-La Roche
• 7.3: Thermo Fisher Scientific
• 7.4: Siemens Healthcare
• 7.5: Bio-Rad Laboratories
• 7.6: General Electric
• 7.7: Koninklijke Philips
• 7.8: Toshiba Corporation
• 7.9: Agilent Technologies
• 7.10: Illumina